hotspot -WSS

hotspot

author：Wikipedia 2025-08-12 11:29:07 - browse：25

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The Karikó problem: Lessons for funding basic research

focus

WSS

What will Novo Nordisk's VC do with its influx of cash?

Health insurers' Q3 question: how much care are people getting?

Do digital therapeutics have a future in medicine?

The Karikó problem: Lessons for funding basic research

Stop Congress from blocking public access to science

Congressmen charge Covid hearing ‘could have been an email’

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

CDC picks Alphabet's Verily for wasterwater surveillance contract

In Memoriam: Notable people who died in 2023

New oral drug delivery patch is modeled after octopus tentacles

Wildfire smoke exposes gaps in outdoor worker protections

What we need to know about Arena Bioworks

How one medical school became remarkably diverse

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Stop Congress from blocking public access to science

Wikipedia

The stability of $0 premiums in Medicare Advantage

New Ultima Genomics DNA sequencer can read genome for $100

Congress extends some pandemic preparedness programs

Medicare innovation center doesn’t save money, experts say

Woodcock on FDA’s accelerated approval and her next chapter

General Catalyst, Summa Health deal will turn on physician buy

Wikipedia

focus

hotspot

entertainment